Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer

This study has been completed.

Sponsor:

Collaborator:

J~pharma

Information provided by:

Gunma University

ClinicalTrials.gov Identifier:

NCT00826033

First received: January 20, 2009

Last updated: NA

Last verified: January 2009

History: No changes posted

Purpose

L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The investigators evaluated the value of 18F-FMT PET for the assessment of therapy response in patients with lung cancer as compared with that of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) PET.

The patients with lung cancer underwent PET studies with 18F-FDG and 18F-FMT before and after radio-/chemotherapy. The investigators used the ratio of the SUVmax of the mediastinal (N2) lymph node to the SUVmax of the primary tumor (N/P ratio ). All patients were divided into two groups of N/P ratio<1 and N/P ratio≥1, and the survival time was estimated by Kaplan-Meier method.

Condition
Non-Small Cell Lung Cancer


Study Type:	Observational
Study Design:	Time Perspective: Prospective
Official Title:	Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy

Resource links provided by NLM:

Genetics Home Reference related topics: lung cancer

MedlinePlus related topics: Lung Cancer

Drug Information available for: Fluorine Fluoride

U.S. FDA Resources

Further study details as provided by Gunma University:

Groups/Cohorts
Therapy monitoring

Eligibility


Ages Eligible for Study:	20 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

This study was conducted at the Gunma University Hospital.

Criteria

Inclusion Criteria:

primary lung cancer All patients received first-line chemotherapy

Exclusion Criteria:

Patients with diabetus mellitus

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00826033

Locations


Japan
Gunma University Graduate School of Medicine
Gunma, Japan, 371-8511

Sponsors and Collaborators

Gunma University

J~pharma

More Information


ClinicalTrials.gov Identifier:	NCT00826033 History of Changes
Other Study ID Numbers:	Mol Imaing 1
Study First Received:	January 20, 2009
Last Updated:	January 20, 2009
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Gunma University:


Fluorine-18-α-methyltyrosine Positron emission tomography Lung cancer chemotherapy monitoring

Additional relevant MeSH terms:


Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases	Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Fluorides Cariostatic Agents Protective Agents Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 28, 2016

To Top